Record Details

Cost of osteoporosis-related fracture in Italy. Results of the BLOCK study

Farmeconomia

View Archive Info
 
 
Field Value
 
Title Cost of osteoporosis-related fracture in Italy. Results of the BLOCK study
 
Creator Degli Esposti, Luca
Adami, Silvano
Iolascon, Giovanni
Nardi, Alfredo
Pietrogrande, Luca
Resmini, Giuseppina
Rossini, Maurizio
Tarantino, Umberto
Tranquilli Leali, Paolo
Trevisan, Carlo
Cheli, Alessandra
Veronesi, Chiara
Buda, Stefano
 
Subject Pharmacoeconomics; Health economics
Bone fractures; Osteoporosis; Cost-of-illness; Administrative database; Adherence to treatment
 
Description The objectives of the present study were to calculate the cost of illness of osteoporosis and to assess drug utilization patterns in postmenopausal women after a fracture-related hospitalization. The study subjects were enrolled from a large population-based administrative database. Female patients (age ≥ 65 years) who were hospitalized for a typical osteoporotic fracture between 1/1/2000 and 31/12/2005 were included. Patients were classified as exposed/unexposed to treatment according to the presence/absence of at least one prescription for an osteoporosis-related medication in the 6 months following the discharge date. Treatment adherence was calculated for patients who were exposed to bisphosphonate therapy and was defined as at least 80% of treatment coverage during the follow-up period of 18 months after the discharge date. Hospitalizations, medications, diagnostic tests, laboratory tests and specialist visits during the 18-month follow-up period were collected and classified as osteoporosis-related or non-related to osteoporosis. A total of 12,376 patients were included in the study (mean age ± SD, 79.1 ± 7.5 years), out of which 97.9% (n = 12,110) were hospitalized due to an osteoporosis-related fracture and only 2.1% (n = 266) had general osteoporosis diagnosis. Among the 12,110 women with a fracture, 15.2% (n = 1,845) had a subsequent fracture-related hospitalization (63.8% of the patients had hip fracture). Only 32.3% (n = 4,001) of all included patients was exposed to osteoporosis-related medications and out of those patients exposed to bisphosphonates (n = 860) only 34.2% (n = 294) was adherent to therapy. The average cost per patient was € 4,481, of which € 1,089 was for osteoporosis-related and € 3,392 for non-osteoporosis-related items. The average cost of a matching cohort of patients without hospitalizations for fracture was € 2,339. Among osteoporosis-related costs, 87.0% was due to hospitalizations for subsequent fractures, 1.5% was due to subsquent hospitalizations for osteoporosis, 9.0% was due to medications, 2.5% was due to laboratory or diagnostic/ instrumental tests. Osteoporosis costs after a first hospitalization for fracture were relevant (twice the costs for patients without hospitalizations for fracture), evident in the short run (within the first 24 months following the index fracture) and mostly due to re-hospitalizations for a new typical osteoporotic fracture. This is in mainly relatedto a low exposure to pharmacological therapy and to insufficient treatment adherence. This study and publication were supported by Amgen Dompe and GlaxoSmithKline.

 
Publisher SEEd
 
Contributor —
 
Date 2011-09-15
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
—
 
Format text/html
application/pdf
 
Identifier http://journals.edizioniseed.it/index.php/FE/article/view/125
10.7175/fe.v12i3.125
 
Source Farmeconomia. Health economics and therapeutic pathways; Vol 12, No 3 (2011); 99-105
2240-256X
1721-6915
 
Language eng
 
Relation http://journals.edizioniseed.it/index.php/FE/article/view/125/126
http://journals.edizioniseed.it/index.php/FE/article/view/125/127
 
Coverage —
—
—